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Abstract
 
The Epstein-Barr virus (EBV) nuclear antigen (EBNA)1 contains a glycine-alanine repeat
(GAr) domain that appears to protect the antigen from proteasomal breakdown and, as mea-
sured in cytotoxicity assays, from major histocompatibility complex (MHC) class I–restricted
presentation to CD8
 
  
 
T cells. This led to the concept of EBNA1 as an immunologically silent
protein that although unique in being expressed in all EBV malignancies, could not be ex-
ploited as a CD8 target. Here, using CD8
 
  
 
T cell clones to native EBNA1 epitopes upstream
and downstream of the GAr domain and assaying recognition by interferon 
 
  
 
release, we show
that the EBNA1 naturally expressed in EBV-transformed lymphoblastoid cell lines (LCLs) is in
fact presented to CD8
 
  
 
T cells via a proteasome/peptide transporter–dependent pathway. Fur-
thermore, LCL recognition by such CD8
 
  
 
T cells, although slightly lower than seen with
paired lines expressing a GAr-deleted EBNA1 protein, leads to strong and specific inhibition of
LCL outgrowth in vitro. Endogenously expressed EBNA1 is therefore accessible to the MHC
class I pathway despite GAr-mediated stabilization of the mature protein. We infer that
EBNA1-specific CD8
 
  
 
T cells do play a role in control of EBV infection in vivo and might be
exploitable in the control of EBV
 
  
 
malignancies.
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Introduction
 
CD8 T cells combat viral infection through recognition of
peptides produced by proteasomal cleavage of endoge-
nously expressed viral proteins and presented at the in-
fected cell surface as a complex with MHC class I mole-
cules (1). Although several viruses have evolved strategies
that interfere with this presentation pathway at a postpro-
teasomal stage (2), the best example of proteasomal target-
ing involves the EBV, a 
 
  
 
herpesvirus associated with sev-
eral human tumors. This virus persists in vivo through
establishing latent infection in B lymphocytes and in vitro
can transform such cells into permanent lymphoblastoid
cell lines (LCLs; 3). EBV encodes a nuclear antigen, EBV
nuclear antigen (EBNA)1, which is essential for virus ge-
nome maintenance in latently infected cells and is a poten-
tially important immunological target in being the only
viral protein present in all EBV-associated malignancies.
Interestingly, EBNA1 contains an internal glycine-alanine
repeat (GAr) domain that is not required for genome main-
tenance or growth transformation (4), but is thought to
have an immune evasion function. Thus, when the GAr
domain was transferred into a known target antigen for
CD8 T cells (in this case another EBV-latent cycle protein,
EBNA3B), cells expressing the chimaeric antigen were not
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killed by EBNA3B-specific effectors in short-term chro-
mium release assays (5). Subsequent work inserting GAr
sequences into other indicator proteins and measuring
protein stability by biochemical and immunofluorescence
assays showed that GAr conferred resistance in cis to pro-
teasomal digestion, albeit to degrees that depended upon
the precise chimaeric construct (6–9). Although this effect
appeared to provide an explanation for the earlier immu-
nological findings, the relationship between GAr-mediated
protection from proteasomal breakdown and the originally
observed protection from CD8 T cell recognition has re-
mained largely unexplored.
The first hint that EBNA1 might be an immunologically
silent protein came from experiments in a mouse tumor re-
jection model where, unlike certain other EBV-latent pro-
teins, EBNA1 failed to confer immunogenicity to a non-
immunogenic tumor line (10). Stronger support for this
hypothesis came from work with human CD8
 
  
 
T cell
preparations reactivated in vitro from EBV-immune do-
nors. Such cells never showed specific killing of targets ex-
pressing the native EBNA1 protein from a vaccinia vec-
tor, in contrast to the frequent detection of responses that
mapped to other latent cycle antigens, in particular EBNAs
3A, 3B, and 3C (11, 12). However, once the effect of the
GAr domain was known, screening in vitro–reactivated
CD8
 
  
 
T cell clones for lysis of vaccinia-infected targets ex-
pressing a GAr-deleted form of EBNA1 clearly showed
that EBNA1-specific reactivities were present in some in-
dividuals and could be mapped to defined EBNA1 peptide
epitopes presented in the context of particular HLA alleles.
Nevertheless, such epitope-specific clones still did not kill
targets expressing the full-length EBNA1 protein (13, 14).
This implied that such responses to an antigen that in its
endogenously expressed form appeared to be protected
from T cell recognition, must arise through cross-priming
by antigen-loaded dendritic cells in vivo. Furthermore,
such responses were unlikely to be biologically effective in
vivo because they would be incapable of recognizing natu-
rally infected cells or indeed EBV
 
  
 
tumors.
Here we cast doubt on these inferences by showing that
when assayed by IFN-
 
  
 
release, EBNA1 epitope–specific
CD8
 
  
 
T cells can indeed recognize LCLs endogenously
expressing the native EBNA1 protein and, in coculture
assays, such effectors specifically inhibit LCL outgrowth.
Thus, GAr
 
  
 
EBNA1 is not fully protected from the MHC
class I presentation pathway and may yet prove to be an ef-
fective target for T cell–based tumor therapy.
 
Materials and Methods
 
Target Cell Lines.
 
LCLs were established using the reference
EBV strains B95.8, Akata, or Sal (15), or the B95.8-based re-
combinant EBV strains d17 (GAr-deleted; 4), 2828 (EBNA1-
deleted), or 2089 (control; 16). The transporter associated with
antigen processing (TAP)-deficient T2:B35-LCL is as previously
described (17). The EBV
 
  
 
Burkitt lymphoma (BL)-derived Sal-
BL, Chep-BL, and Akata-BL lines used in CD40 ligand induc-
tion experiments are as previously described (18). Although these
lines show differential responses to antibody-mediated CD40 li-
gation, they are all strongly responsive to the more potent stimu-
lus provided by CD40 ligand–expressing mouse L cells (19). All
cell lines were maintained in RPMI 1640 medium supplemented
with 2 mM glutamine and 10% fetal calf serum (standard me-
dium). In LCL mixing experiments, the “donor” and “acceptor”
LCLs were seeded together in a 1:1 ratio and the coculture was
left undisturbed for 7 d.
 
CD8
 
  
 
T Cell Clones.
 
The CD8
 
  
 
T cell clones were gener-
ated from selected EBV-immune donors in equal number by in
vitro reactivation of peripheral blood mononuclear cells with the
autologous B95.8-transformed LCL or with the epitope peptide
as previously described (14), followed by limiting dilution clon-
ing of the polyclonal population in 30% MLA 144 supernatant
and 100 IU/ml recombinant IL-2. Epitope-specific clones were
identified by screening for IFN-
 
  
 
and cytotoxic responses to pep-
tide-loaded target cells, and their antigen specificity was con-
firmed in cytotoxicity assays on target cells expressing the relevant
cognate antigen (GAr-deleted EBNA1 or EBNA3A) from vac-
cinia vectors, as previously described (14). Similar reactivities
were generated by LCL or by peptide stimulation.
 
Cytotoxicity and IFN-
 
  
 
Release Assays.
 
Cytotoxicity was as-
sessed in standard 5-h chromium release assays at known effector/
target ratios. IFN-
 
  
 
release was measured by ELISA. In this assay,
T cells were tested in triplicate microwell cultures against target
cells cultured in Iscove’s modified Dulbecco’s medium (Life
Technologies) containing 10% fetal calf serum and 25 IU/ml re-
combinant IL-2. Numbers of T cells and target cells used per well
are indicated in the figure legends. In some experiments, target
cells were prepulsed with 10
 
 
 
7 
 
M epitope peptide followed by
washing three times with RPMI. After overnight incubation,
culture supernatants were harvested and IFN-
 
  
 
was measured by
ELISA using antibody reagents from Endogen.
 
Inhibition Experiments.
 
Target cells were washed with PBS
and pellets were gently resuspended in citrate buffer phosphate
(0.131 M citric acid, 0.066 M Na
 
2
 
HPO
 
4
 
), pH3, for 3 min on
ice. After neutralization by washing with excess standard me-
dium, target cells were incubated in standard medium for 2 h at
37
 
 
 
C with or without proteasome inhibitors at the indicated
concentration. The cells were then washed, resuspended in stan-
dard medium, and then added as targets to appropriate CD8
 
  
 
T
cell effectors. To check the efficiency with which acid stripping
had removed cell surface peptide, some cells were fixed immedi-
ately after acid stripping by incubating for 1 min with 0.05%
glutaraldehyde followed by quenching with 0.2 M glycine and
washing with PBS, and then resuspended in standard medium
and used as targets as described above. To check the viability of
cells exposed to proteasome inhibitors, some cells were removed
immediately after the 2-h drug treatment and, along with un-
treated cells from the same acid-stripped culture, were washed
and then loaded with exogenous epitope peptide (at a range of
100-fold dilutions from 10
 
 
 
6 
 
to 10
 
 
 
14 
 
M) before use as targets in
the assay.
 
Outgrowth Assays.
 
Target cell lines were seeded into round-
bottom microtest plate wells at one of a range of doubling dilu-
tions from 2 
 
  
 
10
 
4
 
–313 cells/well, with duplicate wells at each
seeding density. Before seeding, some target cells were prepulsed
with 10
 
 
 
7 
 
M epitope peptide followed by washing three times
with RPMI. T cells were added at 10
 
4 
 
cells/well to target cell
cultures and as a control to wells without targets. All cultures
were set up in standard medium without cytokine supplements
and were refed weekly by a half change of medium. Outgrowth
was scored visually at 4 wk and the B cell identity of the growing 
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cultures was confirmed by monoclonal antibody staining for
CD19.
 
Results
 
Effect of the GAr Domain on EBNA1 Processing: Cytotox-
icity Assays.
 
This work used CD8
 
  
 
effector T cell clones
against the four EBNA1 epitopes shown in Fig. 1 A and
referred to as HPV (B
 
*
 
3501-restricted), RPQ and IPQ
(both B
 
*
 
0701-restricted), and VLK (A
 
*
 
0203-restricted).
The EBNA1 specificity of these CD8
 
  
 
clones was in each
case confirmed in cytotoxicity assays against targets exoge-
nously loaded with epitope peptide and targets infected
with a vaccinia expressing GAr-deleted EBNA1 (14; not
depicted). Target LCLs were generated from selected do-
nors by transformation with the reference B95.8 EBV
strain and with a recombinant B95.8 virus, dl7, carrying a
GAr-deleted EBNA1 gene (4). Fig. 1 B shows an immuno-
blot of SDS-PAGE–separated proteins from two such LCL
pairs, probed with the IH4 monoclonal antibody against
the COOH-terminal region of EBNA1 downstream of the
GAr domain. Both wild-type transformants express the
standard 80-kD EBNA1 protein as does the reference
B95.8 cell line itself, whereas the dl7 transformants express
the 52-kD GAr-deleted protein. These LCLs are identical
in their expression of the other EBV-latent cycle proteins
(unpublished data).
Recognition of such LCL target pairs by EBNA1-spe-
cific effectors was then tested in conventional 5-h chro-
mium release assays. Fig. 1 C shows data from three CD8
 
 
 
T cell clones, c32, c42, and c2, illustrating the overall range
of results seen with effectors specific for the B
 
*
 
3501-
restricted HPV epitope. These clones mediated 20–30%
specific lysis of two LCLs, RT-dl7a and RT-dl7b, inde-
pendently established from a B
 
*
 
3501
 
  
 
donor and express-
ing the GAr-deleted form of EBNA1. By contrast, lysis of
the paired RT-B95 line and other B
 
*
 
3501
 
  
 
LCLs express-
ing wild-type EBNA1 was either indistinguishable from the
very low backgrounds seen with HLA-mismatched LCLs
or just above that background but in a range (5–10%) that
is not usually considered significant in chromium release as-
says. Fig. 1 C also shows data from two representative
CD8
 
  
 
T cell clones, YPL c39 and c100, specific for a
different B
 
*
 
3501-restricted epitope, YPLHEQHGM, de-
rived from the EBNA3A protein. These effectors killed all
B
 
*
 
3501
 
  
 
LCLs at similar levels whether they carried wild-
type virus or the dl7 recombinant, showing that the two
types of LCLs were not inherently different in their suscep-
tibility to T cell–mediated lysis.
Similar assays were conducted with CD8
 
  
 
T cell clones
to the two HLA-B
 
*
 
0701–restricted EBNA1 epitopes, RPQ
and IPQ, for which HLA-matched dl7 and wild-type tar-
get lines were again available. Such clones showed only
low level killing of the dl7 transformant and no specific ly-
sis of a number of wild-type B
 
*
 
07.01
 
  
 
LCLs. Likewise,
CD8
 
  
 
clones specific for the HLA-A
 
*
 
0203–restricted epi-
tope VLK showed no detectable killing of A
 
*
 
0203
 
  
 
wild-
type LCLs (unpublished data).
Figure 1. EBNA1-specific CD8  T cell recognition of LCLs measured
by cytotoxicity. (A) Schematic diagram of wild-type EBNA1 protein
showing the sequence of CD8  epitopes. Numbers refer to coordinates in
the 641–amino acid sequence of the B95.8 strain EBNA1 protein. (B) Im-
munoblot of SDS-PAGE–separated protein extracts from the B95.8 cell
line, B95.8 virus-transformed LCLs, RT (B95), and NA (B95), expressing
wild-type EBNA1 and from the corresponding dl7 virus transformants,
RT (dl7a) and NA (dl7), expressing GAr-deleted EBNA1. BJAB is an
EBV  B lymphoma cell line. The blot is probed with the EBNA1-specific
monoclonal antibody IH4. (C) Results of 5-h chromium release assays
in which B*3501-restricted CD8  T cell clones specific for the HPV
(EBNA1) epitope or for the YPL (EBNA3A) epitope were used as effec-
tors on a common panel of LCL targets. Targets included two dl7 virus
transformants from B*3501  donor RT, RT-LCL (dl7a), and RT-LCL
(dl7b) expressing GAr-deleted EBNA1, three B*3501  LCLs from donors
RT, GT, and IM transformed either with B95.8 virus (for RT and GT) or
by spontaneous outgrowth with the donor’s own EBV strain (for IM), and
two B95.8 LCLs from B*3501  donors CM and DH. Results are shown
as percent-specific lysis at effector/target ratios of 5:1 and 2.5:1. 
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Effect of the GAr Domain on EBNA1 Processing: IFN-
 
  
 
Re-
lease Assays.
 
In earlier work, we described CD8
 
  
 
T cell
clones reactivated in vitro against EBV-latent cycle antigens
other than EBNA1, which were clearly EBV epitope and
antigen specific in their ability to kill target cells exoge-
nously loaded with synthetic epitope peptide or overex-
pressing the relevant target antigen from a vaccinia vector,
yet which failed to kill naturally infected LCL targets in
conventional cytotoxicity assays (20). While studying the
basis of this phenomenon, we found that such clones do
show specific, HLA class I–restricted recognition of unma-
nipulated LCL targets when measured by ELISA for IFN-
 
 
 
release (unpublished data). Fig. 2 A shows data obtained
when three HPV-specific CD8
 
  
 
clones, again representa-
tive of the complete range, were retested on similar target
cell panels using this more sensitive assay. Now all clones
showed significant recognition of three different wild-type
B
 
*
 
3501
 
  
 
LCLs at levels that though below those seen for
the RT-LCL (dl7a) transformant, were clearly well above
the background shown by HLA-mismatched LCL controls.
We went on to compare the efficiency of dl7 and wild-
type LCL recognition by representative EBNA1-specific
clones in titration assays, varying the numbers of either ef-
fector or target cells added. Fig. 2 B shows data from such
an experiment assaying two HPV-specific clones, c32 and
c33, against the RT (dl7a) and RT (B95) LCL pair. Assay-
ing different numbers of effectors against a standard num-
ber of targets (Fig. 2 B, left), levels of wild-type LCL rec-
ognition by the HPV-specific clones were consistently
40–70% of those seen against the dl7 transformant. A simi-
lar pattern was observed when assaying a standard number
of HPV-specific effectors against different numbers of tar-
gets (Fig. 2 B, right). Interestingly, when we repeated
these experiments using ELISPOT assays (21) as a read
out, the different levels of response were apparent not in
the numbers of T cells that responded but in the intensity
of the IFN-
 
  
 
produced per responding cell (not depicted).
Fig. 2 B also shows the results obtained in the same titra-
tion assays with a CD8
 
  
 
T cell clone (c98) specific for the
YPL epitope. Like other YPL-specific effectors tested, this
Figure 2. EBNA1-specific CD8  T cell recognition
of LCLs measured by IFN-  release. (A) Three CD8 
T cell clones specific for the HPV/B*3501 epitope
were tested against a panel of B*3501  and B*3501 
LCL targets transformed either with wild-type B95.8
virus or with the dl7 strain expressing GAr-deleted
EBNA1. T cells and LCL targets were both seeded at
104 cells/well. As controls, T cells alone were tested in
the presence of 10 7 M HPV epitope peptide or with
no peptide. (B) The efficiency of RT-LCL (B95) and
RT-LCL (dl7a) target recognition was assessed in titra-
tion assays using two HPV (EBNA1)–specific CD8  T
cell clones and one YPL (EBNA3A)–specific clone.
The effect of titrating numbers of effector and target
cells are shown on the left and right, respectively.
When titrating numbers of effectors, LCL targets were
added at 104 cells/well, and when titrating numbers of
targets, effectors were added at 5   103 cells/well. Re-
sults represent the mean values of IFN-  release mea-
sured from triplicate cultures ( SD). 
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clone did not discriminate between the two types of target
LCLs.
The greater sensitivity of IFN-
 
  
 
release assays now al-
lowed us to examine target cell recognition by CD8
 
  
 
T cell
clones to the other EBNA1 epitopes. As shown in Fig. 3
A, three clones specific for the B*0701-restricted RPQ
epitope, though giving different absolute levels of response,
all showed reproducible recognition of the wild-type LCL
from a B*0701  donor NA, again at levels around 50–70%
of that seen against the paired dl7 transformant and clearly
well above the background shown by HLA-mismatched
LCLs. This assay also includes another pair of target LCLs
established from a B*0701  donor MD, one (MD-B95)
transformed with recombinant virus containing the com-
plete B95.8 genomic sequence, the other (MD-dE1) trans-
formed with a recombinant from which the entire EBNA1
gene has been deleted, the genome maintenance function
of EBNA1 having been rendered redundant by integration
of the virus genome into host cell DNA (16). There was
clear recognition of the wild-type but not the EBNA1-
deleted LCL, further confirming that recognition is abso-
lutely dependent upon EBNA1 being expressed in the tar-
get cells. Similar results to the above were observed with
the one available CD8  T cell clone specific for a sec-
ond B*0701-restricted EBNA1 epitope, IPQ (unpublished
data). Fig. 3 B shows data from three representative clones
specific for the A*0203-restricted EBNA1 epitope, VLK.
Though there were no dl7 transformants available as inter-
nal standards in this case, all three VLK-specific clones clearly
recognized wild-type EBNA1-expressing LCLs from A*0203 
donors but not from HLA-mismatched donors, even from
donors with other A*02 subtype alleles.
Requirements for Processing of Endogenously Expressed
GAr  EBNA1. Subsequent experiments aimed to iden-
tify the pathway whereby endogenously expressed wild-
type EBNA1 was presented to CD8 T cells. We first exam-
ined the situation in EBV  BL cell lines that have retained
the original tumor-like “group I” phenotype in vitro. Com-
pared with LCLs, such lines show more limited patterns of
EBV-latent antigen expression usually restricted to EBNA1
only and, most importantly, are deficient in their capacity
to process endogenously expressed antigen via the conven-
tional proteasome/TAP-dependent pathway (22). Here we
used two EBV  BL cell lines that are known to have this
processing deficiency, the B*3501  Sal-BL line and the
B*0701  Chep-BL line. As controls, we used LCLs gener-
ated from the normal B cells of these same patients by in
vitro transformation either with their own resident EBV
strain (in the case of Sal-LCL) or with the B95.8 strain (in
the case of Chep-LCL). The EBNA1 immunoblot of pro-
tein extracts from these BL/LCL pairs is shown in Fig. 4 A,
confirming that the BL lines express the native EBNA1
protein at levels at least equal to those seen in the matching
LCLs. Furthermore, sequencing the EBNA1 gene in the
Sal-BL and Chep-BL virus strains confirmed that the rele-
vant epitope sequences, HPV and RPQ, respectively, were
conserved (not depicted). As shown in Fig. 4 A, three
CD8  T cell clones specific for the HPV/B*3501 epitope
recognized the Sal-LCL as expected, but did not recognize
the EBNA1-expressing Sal-BL target unless this was exog-
enously coated with synthetic epitope peptide. Likewise,
three clones specific for the RPQ/B*0701 epitope recog-
nized the Chep-LCL but not Chep-BL cells unless the lat-
ter were peptide coated. As a specificity control, in each
case there was no recognition of a peptide-coated HLA-
mismatched BL or LCL target.
The deficiency in proteasome/TAP-dependent antigen
processing can be transiently reversed in BL cell lines by
CD40 ligation, restoring processing function toward LCL-
Figure 3. B*0701- and A*0203-restricted CD8  T cell recognition of
endogenously expressed EBNA1. (A) Three CD8  T cell clones specific
for the RPQ/B*0701 epitope were tested against a panel of B*0701  and
B*0701  LCL targets transformed with the wild-type EBV strain B95.8,
against the B*0701  NA-LCL (dl7) carrying an EBNA1 gene deleted for
the GAr-coding sequence, or against the B*0701  MD-LCL (dE1) carry-
ing an EBV genome from which the EBNA1 gene has been completely
deleted. As a positive control, T cells were tested against MD-LCL (dE1)
cells that had been precoated with the target epitope peptide RPQ. (B)
Three CD8  T cell clones specific for the VLK/A*0203 epitope were
tested against a panel of HLA-matched and -mismatched LCL targets
transformed with the wild-type EBV strain B95.8. As a positive control,
T cells were tested with 10 7 M VLK epitope peptide alone. T cells were
tested at 104 cells/well and LCL targets were tested at 2   104 cells/well.
Results expressed as in Fig. 2.CD8 T Cells Recognize Endogenously Expressed EBNA1 1414
Figure 4. Presentation of EBNA1 to CD8  T cells does not occur in cells with
defects in the proteasome/TAP-dependent processing pathway. (A) Top: EBNA1
immunoblot (as in Fig. 1 B) of protein extracts from the Sal-BL/Sal-LCL and Chep-
BL/Chep-LCL pairings. X50-7 is a standard B95.8 virus-transformed LCL. Middle:
Three CD8  T cell clones specific for the HPV/B*3501 epitope were tested against
the B*3501  Sal-BL/Sal-LCL pair of targets and against Sal-BL cells precoated with
HPV peptide. Control targets were the B*3501  RT-LCL (B95) and an HLA-mis-
matched LCL precoated with HPV peptide. Bottom: Three T cell clones specific for
the RPQ/B*0701 epitope were tested against the B*0701  Chep-BL/Chep-LCL
pair of targets and against Chep-BL cells precoated with RPQ peptide. Control tar-
gets were the B*0701  GT-LCL (B95) and an HLA-mismatched LCL precoated
with RPQ peptide. (B) Top panels: CD8  T cell clones specific for the B*3501-
restricted epitopes HPV (EBNA1) or YPL (EBNA3A) were tested against the Sal-
BL/Sal-LCL pair of targets and against Sal-BL cells preexposed for 2 d to CD40
ligand–expressing mouse L cells (L CD40L). Control targets included the Chep-
BL/Chep-LCL pair, Chep-BL cells similarly exposed to L CD40L cells, and
L CD40L cells themselves. Bottom: CD8  T cell clones specific for the RPQ/
B*0701 epitope were tested against the Chep-BL/Chep-LCL pair and against Chep-
BL cells preexposed as described above to L CD40L cells. Control targets included
the HLA-mismatched Akata BL line, with and without preexposure to L CD40L
cells, the HLA-mismatched RT-LCL (Ak) transformed with the Akata virus strain,
and L CD40L cells themselves. (C) CD8  T cell clones against the HPV and YPL
epitopes were tested against the TAP  T2:B35 LCL target line precoated or not with
the relevant epitope peptide. Control targets included the B*3501  RT-LCL (B95)
and an HLA-mismatched LCL precoated with the relevant peptide. In all the above
assays, T cells were tested at 1,000–10,000 cells per well and targets at 25,000 cells
per well. Results expressed as in Fig. 2.Lee et al. 1415
like levels (23). Accordingly, Fig. 4 B shows data obtained
on target lines used with or without previous exposure for
2 d to CD40 ligand–transfected mouse L cells. CD40 liga-
tion clearly rendered the Sal-BL recognizable by HPV-spe-
cific T cell clones and the Chep-BL line recognizable by
RPQ-specific clones, in each case to levels approaching
that seen for the paired LCL. Such recognition was specific
because responses to CD40-ligated but HLA-mismatched
BL cells remained completely negative. Normally in such
assays involving BL cells, there is no other viral protein
available as a source of reference epitopes because most
group I BL lines limit their EBV-latent protein expression
to EBNA1. However, recent work identified Sal-BL as an
unusual line in which viral antigen expression extends to
include the immunodominant EBNA3A, 3B, and 3C pro-
teins (15). Therefore, this allowed us to use the B*3501-
restricted YPL as a reference epitope whose processing and
presentation from endogenously expressed EBNA3A is
known to involve the proteasome/TAP pathway (17).
As expected, unmanipulated Sal-BL cells were unable to
present endogenously expressed EBNA3A to YPL-specific
effectors but acquired the capacity to do so after CD40 li-
gation (Fig. 4 B), confirming that the conventional HLA
class I processing pathway was indeed inoperative in Sal-BL
cells but could be activated by CD40 ligation.
To further examine the TAP dependence of EBNA1
processing, we tested the capacity of EBNA1-specific ef-
fectors to recognize endogenously expressed antigen in a
B*3501 transfectant of the TAP1/TAP2  T2-LCL. As
shown in Fig. 4 C, HPV-specific clones recognized a wild-
type EBNA1-expressing LCL but not the T2:B35 line. As
controls, T2:B35 cells were recognized if loaded with epitope
peptide, whereas a peptide-coated HLA-mismatched LCL
was not. This is the result expected if EBNA1 is being pro-
cessed by the conventional HLA class I pathway because
we already know that the HPV epitope, when processed
and presented from GAr-deleted EBNA1 in vaccinia assays,
is TAP dependent (13). Results obtained in parallel with
two YPL-specific clones followed a similar pattern in that
unmanipulated T2:B35 cells were again not recognized,
confirming the known TAP dependence of this epitope’s
presentation from EBNA3A (17).
To further examine the proteasome dependence of
EBNA1 processing, we performed a series of assays in
which, according to a previously described protocol (24),
LCL cells were first stripped of surface HLA class I–bound
peptides by brief acid treatment at pH3, washed, and then
cultured for 2 h in the presence or absence of protea-
some inhibitors before being washed and added as targets
in overnight assays with EBNA1-specific CD8  T cells.
Therefore, the levels of IFN-  release observed reflect the
reappearance of specific HLA–peptide complexes at the
LCL surface within the 16-h assay period, and can be com-
pared with those induced by untreated (nonstripped) cells
included in these assays as positive control targets. As a fur-
ther control, we checked how well acid stripping had re-
moved cognate HLA–peptide complexes by glutaraldehyde
fixing some cells immediately after stripping and including
Figure 5. Presentation of EBNA1 to CD8  T cells is blocked by inhib-
itors of proteasome function and requires endogenously expressed anti-
gen. (A) The B*3501  RT-LCL (B95) and RT-LCL (dl7a) target cells
were acid stripped to remove surface HLA class I–bound peptides,
washed, and incubated either in standard medium or in the presence of 20
 M lactacystin or 0.4  M epoxomicin. The target cells were then
washed extensively and mixed with CD8  T cell clones specific for the
HPV/B*3501 epitopes. Control targets included cells of the same line
that had been acid stripped and then immediately fixed with glutaralde-
hyde (Fixed), cells of the same line that had not been acid stripped or ex-
posed to inhibitors (untreated), and cells of an HLA-mismatched B95.8
virus–transformed LCL. In a parallel experiment to check for nonspecific
toxicity of the inhibitors, the above acid-stripped LCL cells were exposed
to epitope peptide dilutions after their 2-h treatment with proteasome in-
hibitors, and then washed and tested as targets. These cells stimulated
IFN-  release after exposure to peptide concentrations as low as 10 10 M
just as efficiently as did acid-stripped cells that had not been inhibitor
treated. (B) The acceptor B*0701 /EBNA1  MD-LCL (dE1) was mixed
with an equal number of cells from the donor B*0701 /EBNA1  CM-
LCL (B95), and the mixture was cocultivated for 7 d before being used as
targets for CD8  T cell clones specific for the RPQ/B*0701 epitope.
Control targets included the donor and acceptor LCLs alone, assayed
pulsed or not pulsed with the RPQ peptide, the donor   acceptor cocul-
tures pulsed with RPQ peptide, and the B*0701  EBNA1  cell line MD-
LCL (B95). Results expressed as in Fig. 2.CD8 T Cells Recognize Endogenously Expressed EBNA1 1416
these cells as targets. Fig. 5 A, top, shows typical results
from one such experiment using the wild-type RT-LCL as
a target and two HPV-specific CD8  T cell clones as effec-
tors. The acid-stripped target cells that had not been ex-
posed to inhibitors showed a complete recovery of epitope
peptide display to positive control levels. However, acid-
stripped targets then exposed to either of two irreversible
proteasome inhibitors, lactacystin (25) and epoxomicin
(26), showed very poor recovery, stimulating levels of
IFN-  release only just above the low baseline induced by
target cells fixed immediately after stripping. A third pro-
teasome inhibitor, MG132 (27), also impaired recovery but
to a lesser extent (not depicted), reflecting the fact that its
action is reversible. The effects of lactacystin and epoxomi-
cin were not due to some nonspecific drug toxicity because
acid-stripped cells reloaded with exogenous epitope pep-
tide after drug treatment remained efficient stimulators of
an IFN-   response (Fig. 5, legend). The processing of
wild-type EBNA1 to CD8  T cells appeared to be just as
sensitive to proteasome inhibition as that of GAr-deleted
EBNA1 because similar results were observed in a parallel
acid stripping assay using the RT-dl7a LCL as the target
cell line (Fig. 5 A, bottom).
An involvement of the proteasome in EBNA1 process-
ing can still be reconciled with GAr-mediated protection if
the protein is being handled by a cross-priming route, i.e.,
if EBNA1 were released from dying cells, phagocytosed by
neighboring cells, and partially broken down by phagoso-
mal proteases to GAr-free fragments that are then retro-
transported to the proteasome (28, 29). Therefore, we set
up experiments to look for evidence of such cross-priming
by mixing a B*0701  donor LCL-expressing wild-type
EBNA1 with the B*0701  but EBNA1  acceptor LCL,
MD (dE1), and looking for cross-presentation of EBNA1
using CD8  T cells specific for the B*0701-restricted RPQ
epitope. Results from one representative experiment (Fig.
5 B) show that even leaving donor and acceptor LCLs un-
disturbed in coculture for 7 d did not lead to detectable
recognition by any of three RPQ-specific CD8  clones.
Yet clearly MD (dE1) acceptor cells were still present in
the cocultures because the mixed population could present
exogenously loaded RPQ peptide almost as efficiently as
the MD (dE1) LCL itself. As controls in the same as-
says, these clones did not recognize the B*0701  donor
line, CM-LCL (B95), with or without peptide, but did
recognize the wild-type MD-LCL (B95) included as an
EBNA1  B*0701  target.
Effect of EBNA1-specific T Cell Recognition on EBV-infected
B Cell Growth. A final set of experiments asked
whether these EBNA1-specific CD8  T cells could af-
fect the long-term growth and survival of EBNA1-
expressing B cells. Various EBV  B cell lines were
seeded in microtest plate wells at a range of input cell
numbers (20,000–313 per well), either alone or in the
presence of added CD8  T cells (10,000 per well) from
clones of known specificity. Cultures were maintained
by weekly refeeding and were assayed for B cell line
outgrowth after 4 wk. By this time, outgrowth was im-
mediately apparent from microscopic inspection of the
wells, and we confirmed by CD19 staining that this re-
flected growth of the target B cell line and not surviving
Figure 6. EBNA1-specific CD8  T cells inhibit the in vitro outgrowth
of EBV-transformed LCLs of the appropriate HLA type. EBV  target B
cell lines were seeded in microtest plate wells at a range of input cell
numbers (20,000–313 per well), either alone or in the presence of added
CD8  T cell clones (10,000 per well) specific for the HPV/B*3501 or
YPL/B*3501 epitopes. For each target, results are expressed as the mini-
mum target cell seeding required for successful outgrowth from the dif-
ferent types of coculture. The corresponding value for target cells in the
absence of T cells is shown as a dotted horizontal line. Targets included
B*3501  and B*3501  LCLs transformed either with B95.8 virus or with
the dl7 strain as well as the TAP  LCL T2:B35 and the processing-defi-
cient B*3501  Sal-BL line, both either pulsed or not pulsed with the ap-
propriate epitope peptide HPV or YPL. Cultures were assessed for cell
growth after 4 wk. Control cultures set up with T cells alone contained
no viable cells by that stage.Lee et al. 1417
T cells. Control cultures set up with T cells alone con-
tained no viable cells at 4 wk.
Fig. 6 presents the results of one such experiment in-
volving a variety of target B cell lines each seeded alone
and in cocultures with three CD8  T cell clones specific for
the B*3501-restricted EBNA1 epitope HPV and with two
clones specific for the B*3501-restricted EBNA3A epitope
YPL. Results are expressed as the minimum target cell
seeding giving successful outgrowth in each case compared
with the growth of target cells alone (dotted line) showing
the effects of T cell addition. The key findings are shown
in Fig. 6 A, where the three HPV-specific clones all signif-
icantly inhibited outgrowth not just of the B*3501  LCL,
RT (dl7a), expressing a GAr-deleted EBNA1 protein, but
also of two B*3501  LCLs, RT (B95) and PB (B95), ex-
pressing wild-type EBNA1. Indeed, the degree of inhibi-
tion seen in these cocultures was similar to that mediated in
the same assay by the two YPL-specific clones. Note that
in all cocultures where the addition of T cells had pre-
vented B cell outgrowth, there were no viable cells of ei-
ther type detectable at 4 wk. These effects were not non-
specific consequences of coculture because three B*3501 
LCLs, SC (B95), YC (B95), and CM (B95), showed no
significant inhibition of outgrowth from either HPV- or
YPL-specific clones. Indeed, with some of these HLA-mis-
matched combinations we even observed a slight enhance-
ment of LCL outgrowth from low target cell seedings. Fig.
6 B shows outgrowth data from processing-deficient target
lines that again parallel the IFN-  results seen earlier with
these same lines (Fig. 4). Thus, the T2:B35-LCL was
not growth inhibited by HPV- or YPL-specific effectors,
whereas the same targets were strongly inhibited if pre-
exposed to the relevant epitope peptide. Likewise, both
HPV- and YPL-specific effectors did not affect outgrowth
of the B*3501  Sal-BL line, unless these cells were first
epitope loaded.
Importantly, the ability to inhibit target cell outgrowth
through recognition of endogenously expressed EBNA1
was not restricted to HPV-specific T cells. Thus, we re-
peated the coculture experiments using two VLK-specific
clones, VLK c16 and c76, which had clearly shown specific
LCL recognition by IFN-  release (Fig. 3) but, unlike the
HPV effectors, had never given any hint of target cell kill-
ing in chromium release assays. When tested on a range of
wild-type (B95.8) LCLs, these clones strongly inhibited
outgrowth of A*0203  lines without affecting that of HLA-
mismatched controls (not depicted).
Discussion
All previous studies of GAr-mediated protection from
cytotoxic T cell recognition have either looked at the
processing of indicator epitopes from GAr- or epitope-
inserted chimaeric proteins (5, 30), or have examined na-
tive EBNA1 epitope processing using nonphysiologic sys-
tems for EBNA1 expression (13, 14, 31). Here, to assay the
effect of GAr in its natural context, we used a range of CD8 
T cell clones specific for native EBNA1 epitopes and pairs
of EBV-transformed target LCLs expressing either full-
length EBNA1 or an EBNA1 from which all but 13 of the
original 239 GAr residues had been deleted (4). We con-
sider it very unlikely that this residual 13–amino acid se-
quence has any immunologic effect because GAr functions
are known to be length dependent (32) and short GAr in-
serts are only active in particular circumstances (7). As a
read out, we switched from cytotoxicity to cytokine release
because, unlike the experience of others with influenza-
specific human T cells (33), we found that IFN-  produc-
tion was a more sensitive indicator of target cell recogni-
tion by CD8  T cell clones reactive to EBV-latent cycle
antigens. The IFN-  release assays clearly show that LCL
cells expressing a wild-type GAr  EBNA1 protein are
recognized by CD8  T cell clones against four different
EBNA1 epitopes situated both upstream and downstream
of the GAr domain. Comparing clones to the upstream
RPQ and downstream HPV epitopes, recognition of the
wild-type EBNA1 protein was in both cases within 40–
80% of that seen for the GAr-deleted protein. We con-
clude that for EBNA1 expressed in its natural setting in
LCL cells, the GAr domain affords the protein only partial
protection from CD8  T cell recognition. In light of this,
we must qualify our original proposition that the EBNA1-
specific CD8  responses found in infected individuals must
necessarily have been induced by cross-priming in vivo
(13, 14). Because EBNA1 epitopes are presented on the in-
fected cell surface, it is conceivable that the response to
EBNA1 (and to other EBV-latent antigens) is primed via a
direct interaction between the CD8  T cell repertoire and
naturally infected B cells.
The inability of EBNA1-specific CD8  T cell clones to
recognize either EBV  BL cells or the TAP-deficient T2:
B35 LCL was consistent with the view that in standard
LCLs, wild-type EBNA1 is being processed via the con-
ventional proteasome/TAP-dependent pathway. This was
further supported by experiments in which three known
inhibitors of proteasomal function, lactacystin (25, 34), ep-
oxomicin (26), and MG132 (27), all blocked the reap-
pearance of EBNA1 peptide–HLA class I complexes on
the surface of wild-type LCLs after the removal of exist-
ing complexes by acid stripping. Similar results were ob-
tained whether the wild-type GAr  or the dl7 GAr-deleted
EBNA1 was the epitope source, so the processing of both
antigens appears equally proteasome dependent. We asked
whether the target for this processing might actually be an-
tigen acquired by intercellular transfer within LCL cultures,
a route which for wild-type EBNA1 could involve an ini-
tial breakdown by phagosomal proteases into GAr-free
fragments that after retrotransport to the cytosol would be
susceptible to proteasomal digestion (35, 36). However,
under standard conditions of LCL culture, mixtures of ap-
propriate donor and acceptor LCLs gave no evidence of
such antigen transfer and subsequent processing. We be-
lieve that this is a significant negative result because the
same LCL mixing protocol has successfully demonstrated
the intercellular transfer of EBNAs into the HLA class II
pathway in such cells (unpublished data). Although we doCD8 T Cells Recognize Endogenously Expressed EBNA1 1418
not rule out that intercellular transfer of antigen into the
class I pathway may occur at some level in LCLs, our re-
sults clearly show that this is not the main source of
EBNA1 epitope display. We infer that endogenously ex-
pressed EBNA1 is indeed targeted intracellularly by the
proteasome despite the presence of the GAr domain. Two
studies contemporaneous with this work have come to
similar conclusions, although in both cases the evidence
comes from experiments where EBNA1 fusion proteins
have been expressed by transfection in epithelial cell lines
(38, 39).
In the same context, another recent study has identified a
second function of the GAr domain, whether in native
EBNA1 or fused at the NH2 or C terminus of an indicator
protein (OVA), which is to specifically inhibit translation
of its own mRNA (37). Although the mechanism of this
effect remains unknown, GAr was a more effective inhibi-
tor of translation when fused to OVA at the NH2 than at
the C terminus, whereas the two fusion proteins, once syn-
thesized, appeared to be equally well protected from pro-
teasomal digestion. When these fusion proteins were ex-
pressed by transient transfection in mouse cells, the N
terminally tagged fusion was completely protected from
recognition by CD8  T cells to an H2-Kb–restricted OVA
epitope, whereas the C terminally tagged fusion was only
partially protected. The authors argued that the effect of
GAr on antigen presentation reflected more its capacity to
inhibit translation than to stabilize the protein once it was
synthesized. This is consistent with the view that defective
ribosomal products (DriPs), recently synthesized and im-
mediately marked for proteasomal digestion, are a more
important source of peptides entering the MHC class I
pathway than is the steady state turnover of mature proteins
(28, 29).
Our findings on the processing of native EBNA1 can
also be accommodated within this view. Thus, in EBV-
transformed LCLs, although the GAr domain may regulate
EBNA1 mRNA translation to some extent, full-length
EBNA1 has to be synthesized de novo with each cell cycle
to maintain the levels of this important protein partitioned
to daughter cells. Defective products from such synthesis
could therefore provide new substrates for the proteasome.
If this is indeed the case, the fact that EBNA1 epitopes lo-
cated upstream and downstream of GAr are equally well
presented implies that the DriPs in question are misfolded
full-length products and not N-terminal fragments whose
extension has been stalled by the GAr domain. It remains
to be seen whether GAr  DriPs are directly accessible to
the proteasome or whether they require initial cleavage by
another cytosolic protease. Whatever the detail, the avail-
able evidence now strongly suggests that the GAr domain is
more effective as a stabilizing influence on the mature
EBNA1 protein than as a protective influence against
CD8  T cell recognition. This would support our earlier
contention, made from the study of EBNA1 homologues
in simian   herpeviruses (40), that the principal evolution-
ary force driving acquisition of the GAr domain has not
been immune pressure per se but the requirement that
EBNA1, the virus genome maintenance protein that is
centrally important for virus persistence in cells, be pro-
tected from proteolysis.
Finally, although EBNA1 epitope-specific CD8 clones
did not kill wild-type LCL targets in short-term cytotoxic-
ity assays, we found clear evidence that they could prevent
the longer term outgrowth of these cells in vitro. These in-
hibitory effects, culminating in death of the LCL, were
specific and correlated precisely with the results of IFN- 
release assays in that recognition was only observed if tar-
get cells expressed the relevant HLA-restricting allele and
could process antigens via the proteasome/TAP pathway.
The mechanism whereby these T cells inhibit LCL out-
growth is clearly of interest and is now the subject of fur-
ther investigations. However, given these results, we infer
that EBNA1-induced CD8 responses will be biologically
effective against natural EBV infection in vivo in the same
way as CD8  T cells against other latent cycle proteins,
namely in controlling the virus-driven expansions of la-
tently infected B cells that are a major feature of primary
infection and may also recur at any time during virus per-
sistence (3). Furthermore, our results imply that EBNA1-
specific CD8  T cells might be exploited therapeutically,
possibly along with EBNA1-specific CD4  T cells (41), to
target EBV  malignancies. This is particularly relevant in
the context of EBV  Hodgkin’s disease and nasopharyngeal
carcinoma where, in the absence of the immunodominant
EBNA3 antigens, EBNA1 is one of the few virus proteins
expressed and where evidence to date suggests that the pro-
teasome/TAP-dependent pathway of antigen presentation
remains intact in tumor cells (42–44). This contrasts with
the situation in BL where EBNA1 is usually the only avail-
able antigen but where EBNA1-specific CD8  T cells could
only be effective if combined with protocols designed to
restore antigen-presenting capacity in the tumor. These
findings also have important implications for strategies that
seek to silence potentially immunogenic therapeutic pro-
teins by GAr domain insertion (45). Such fusion proteins
will not only be capable of inducing CD8  T cell responses
in vivo, but cells expressing those proteins are likely to be
recognized by the effectors thus induced.
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